Skip to content

Hyaluronic Acid and I-PRF Mixture for TMJ Disc Displacement Management

Evaluation of Hyaluronic Acid and I-PRF Mixture for Intra-articular Injection Following Arthrocentesis in The Management of TMJ Reducible Disc Displacement: A Four Arm Comparative Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07683650
Enrollment
72
Registered
2026-07-06
Start date
2026-01-06
Completion date
2027-02-01
Last updated
2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TMJ Disc Displacement With Reduction

Keywords

TMJ, Disc Displacement With Reduction, Arthrocentesis, Hyaluronic Acid, I-PRF

Brief summary

The aim of this study is to evaluate the efficacy of hyaluronic acid and I-PRF mixture for intra-articular injection following arthrocentesis in the management of TMJ reducible disc displacement.

Detailed description

The purpose of this four-arm comparative clinical trial is to evaluate the efficacy of a combined intra-articular injection of Hyaluronic Acid (HA) and Injectable Platelet-Rich Fibrin (i-PRF) following arthrocentesi in patients suffering from temporomandibular joint (TMJ) reducible disc displacement. All eligible participants will undergo standard TMJ arthrocentesis using Ringer's lactate solution to flush out inflammatory mediators and disrupt intra-articular adhesions. Patients will be randomly assigned to one of four treatment protocols to compare therapeutic outcomes: Group I: Arthrocentesis alone (Control). Group II: Arthrocentesis followed by intra-articular injection of Hyaluronic Acid only. Group III: Arthrocentesis followed by intra-articular injection of a Hyaluronic Acid and Betamethasone mixture. Group IV: Arthrocentesis followed by intra-articular injection of a Hyaluronic Acid and I-PRF mixture (Experimental). Clinical outcomes include changes in maximum pain-free mouth opening, lateral/protrusive jaw movements, subjective pain intensity scores and presence or absence of clicking Clinical outcomes will be monitored and evaluated over a 6-month post-operative follow-up period to assess which intervention provides the most effective relief and functional restoration.

Interventions

PROCEDURE18 joints that receive arthrocentesis using 100 ml of ringer lactate solution

18 joints that receive arthrocentesis using 100 ml of ringer lactate solution

PROCEDUREArthrocentesis followed by hyaluronic acid injection

18 joints that receive arthrocentesis using 100 ml of ringer lactate solution followed by intra-articular injection of 1 ml of hyaluronic acid

PROCEDUREArthrocentesis followed by injection of hyaluronic acid and betamethasone mixture

18 joints that receive arthrocentesis using 100 ml of ringer lactate solution followed by intra-articular injection of hyaluronic acid and betamethasone mixture

PROCEDUREArthrocentesis followed by injection of hyaluronic acid and I-PRF mixture

18 joints that receive arthrocentesis using 100 ml of ringer lactate solution followed by intra-articular injection of hyaluronic acid and I-PRF mixture

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 18 - 45 years. 2. Patients with disc displacement with reduction in any of the TMJs. 3. arthralgia. 4. Limited unassisted mouth opening. 5. Co-operative patients.

Exclusion criteria

1. Patients with previous history of TMJ minimally invasive interventions. 2. Patients with autoimmune or connective tissue diseases affecting the joints. 3. Patients with neurological disorders. 4. Patients with a history of condylar fractures or ankylosis. 5. Patients with psychological problems. 6. Patients receiving non-steroidal anti-inflammatory drugs within 48 hours preoperatively, or systemic use of corticosteroids within 2 weeks. 7. Patients on anticoagulants, suffering from platelet function disorders or fibrinogen deficiency. 8. Patients with moderate to severe myogenic pain.

Design outcomes

Primary

MeasureTime frameDescription
Intensity of painpreoperative, one week, one month, 3 months and 6 monthsPain intensity will be evaluated subjectively using Numeric Rating Scale from zero to 10 zero indicates no pain at all 10 indicates the worst pain ever
Maximum interincisal opening, lateral and protrusive movementspreoperative, one week, one month, 3 months and 6 months1. Maximum interincisal opening: the distance in millimeters between the incisal edges of the central incisors in vertical direction at maximum pain free mouth opening, measured using a caliper. 2. Range of lateral and protrusive movements: the distance in millimeters between the upper and lower midlines in horizontal direction on lateral and protrusive movements, measured using a caliper.

Secondary

MeasureTime frameDescription
Clickingpreoperative, one week, one month, 3 months and 6 monthsclicking will be evaluated as either present or absent throughout the follow up intervals

Countries

Egypt

Contacts

CONTACTNada Hamed
hamednada99@mans.edu.eg00201119659235
PRINCIPAL_INVESTIGATORNada Hamed

Faculty of Dentistry Mansoura University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026